AU2018225099B2 - Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates - Google Patents

Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates Download PDF

Info

Publication number
AU2018225099B2
AU2018225099B2 AU2018225099A AU2018225099A AU2018225099B2 AU 2018225099 B2 AU2018225099 B2 AU 2018225099B2 AU 2018225099 A AU2018225099 A AU 2018225099A AU 2018225099 A AU2018225099 A AU 2018225099A AU 2018225099 B2 AU2018225099 B2 AU 2018225099B2
Authority
AU
Australia
Prior art keywords
polysaccharide
kda
protein
serotypes
crm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018225099A
Other languages
English (en)
Other versions
AU2018225099A1 (en
Inventor
Chitrananda Abeygunawardana
Jian He
Joseph G. Joyce
Catherine LANCASTER
John E. MACNAIR
Patrick Mchugh
Luwy MUSEY
Hari PUJAR
Julie M. Skinner
William J. Smith
Emily WEN
John Michael Williams
Michael A. WINTERS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of AU2018225099A1 publication Critical patent/AU2018225099A1/en
Assigned to MERCK SHARP & DOHME LLC reassignment MERCK SHARP & DOHME LLC Amend patent request/document other than specification (104) Assignors: MERCK SHARP & DOHME CORP.
Application granted granted Critical
Publication of AU2018225099B2 publication Critical patent/AU2018225099B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2018225099A 2017-02-24 2018-02-20 Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates Active AU2018225099B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762463216P 2017-02-24 2017-02-24
US62/463,216 2017-02-24
US201762555444P 2017-09-07 2017-09-07
US62/555,444 2017-09-07
PCT/US2018/018729 WO2018156491A1 (en) 2017-02-24 2018-02-20 Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates

Publications (2)

Publication Number Publication Date
AU2018225099A1 AU2018225099A1 (en) 2019-07-25
AU2018225099B2 true AU2018225099B2 (en) 2024-08-22

Family

ID=63254065

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018225099A Active AU2018225099B2 (en) 2017-02-24 2018-02-20 Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates

Country Status (10)

Country Link
US (4) US11090374B2 (https=)
EP (1) EP3589314A4 (https=)
JP (3) JP7680185B2 (https=)
KR (2) KR20240011879A (https=)
CN (1) CN110337307A (https=)
AU (1) AU2018225099B2 (https=)
BR (1) BR112019017560A2 (https=)
CA (1) CA3050120A1 (https=)
MX (3) MX2019009867A (https=)
WO (1) WO2018156491A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2604363C (en) * 2005-04-08 2015-06-16 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN120718167A (zh) 2014-01-21 2025-09-30 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
CN108367063A (zh) * 2015-07-21 2018-08-03 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其试剂盒和用途
ES3024474T3 (en) 2016-12-30 2025-06-04 Vaxcyte Inc Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN110225764A (zh) 2017-01-31 2019-09-10 默沙东公司 制备多糖-蛋白缀合物的方法
ES3048958T3 (en) 2017-01-31 2025-12-12 Merck Sharp & Dohme Llc Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
US11400162B2 (en) 2017-02-24 2022-08-02 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
WO2019050813A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
AU2018328040B2 (en) 2017-09-07 2025-01-16 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
EP3678655A4 (en) * 2017-09-07 2021-05-05 Merck Sharp & Dohme Corp. PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE CARRIER PROTEIN CONJUGATES
CN111065387B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
TWI725359B (zh) 2017-12-06 2021-04-21 美商默沙東藥廠 包含肺炎鏈球菌多醣-蛋白結合物之組合物及其使用方法
JP7397000B2 (ja) 2018-04-30 2023-12-12 メルク・シャープ・アンド・ドーム・エルエルシー 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法
EP3787673A4 (en) 2018-04-30 2022-04-27 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
US12144855B2 (en) 2018-04-30 2024-11-19 Merck Sharp & Dohme Llc Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
KR102879391B1 (ko) * 2018-09-23 2025-10-30 바이오로지칼 이 리미티드 스트렙토코쿠스 뉴모니아에의 정제된 협막 다당류
GEAP202415690A (en) * 2018-12-19 2024-01-10 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CA3136278A1 (en) * 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
MX2021014710A (es) * 2019-06-05 2022-01-18 Merck Sharp & Dohme Llc Un conjugado inmunogenico de polisacarido de neumococo del serotipo 35b- proteina y proceso de conjugacion para preparar el mismo.
CN110804097B (zh) * 2019-10-30 2021-02-26 云南沃森生物技术股份有限公司 一种同时制备两种单克隆抗体的方法
KR20220146451A (ko) * 2020-01-17 2022-11-01 인벤트프라이즈 엘엘씨 다가 스트렙토코커스 백신
EP4101192A4 (en) * 2020-02-03 2024-02-28 Anagog Ltd. DELIVERY OF DISTRIBUTED CONTENT
WO2021219530A1 (en) * 2020-04-28 2021-11-04 Janssen Pharmaceuticals, Inc. Method for identification and quantification of polysaccharides in complex glycoconjugate compositions
JP7804673B2 (ja) 2020-11-10 2026-01-22 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
EP4346893A2 (en) * 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN114965784B (zh) * 2022-06-01 2023-10-27 艾美探索者生命科学研发有限公司 多糖活化度的测定方法
WO2024059161A1 (en) * 2022-09-16 2024-03-21 Merck Sharp & Dohme Llc Method for quantification of polysaccharide content in conjugate vaccines
JP2025537898A (ja) 2022-11-22 2025-11-20 ファイザー・インク コンジュゲートさせた莢膜糖類抗原を含む免疫原性組成物およびその使用
KR20250163977A (ko) 2023-03-30 2025-11-21 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
EP4694921A1 (en) 2023-04-14 2026-02-18 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4701656A1 (en) 2023-04-24 2026-03-04 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025219904A1 (en) * 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041003A2 (en) * 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
EP2865392A1 (en) * 2012-06-20 2015-04-29 SK Chemicals Co., Ltd. Polyvalent pneumococcal polysaccharide-protein conjugate composition
US20150202309A1 (en) * 2014-01-21 2015-07-23 Pfizer Inc. Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof
WO2017013548A1 (en) * 2015-07-21 2017-01-26 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
CA2604363C (en) 2005-04-08 2015-06-16 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
NZ562719A (en) 2005-04-08 2008-12-24 Wyeth Corp Separation of contaminants from streptococcus pneumoniae polysaccharide by pH manipulation
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
PT2074221E (pt) 2006-10-10 2010-09-06 Wyeth Llc Métodos melhorados para a separação de polissacáridos tipo 3 de streptococcus pneumoniae
PT2129693T (pt) 2007-03-23 2017-02-14 Wyeth Llc Processo de purificação abreviado para a produção de polissacáridos capsulares de streptococcus pneumoniae
US8540955B2 (en) 2007-07-10 2013-09-24 Wyeth Llc Process for producing aluminum phosphate
ES2749952T3 (es) 2008-12-18 2020-03-24 Wyeth Llc Procedimiento de control del peso molecular de polisacáridos de Streptococcus pneumoniae usando carbono
KR20110091546A (ko) 2008-12-18 2011-08-11 와이어쓰 엘엘씨 스트렙토코커스 뉴모니에 혈청형 19ａ 폴리사카라이드 분자량을 조절하는 방법
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
PT2575870T (pt) 2010-06-04 2017-02-10 Wyeth Llc Formulações de vacinas
AR084158A1 (es) 2010-12-10 2013-04-24 Merck Sharp & Dohme Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
EP3363806B1 (en) 2012-12-20 2022-11-16 Pfizer Inc. Glycoconjugation process
CN120718167A (zh) 2014-01-21 2025-09-30 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
BR112016016580B1 (pt) * 2014-01-21 2024-01-09 Pfizer Inc Processo para a preparação de um conjugado imunogênico, conjugado imunogênico, composição imunogênica, e vacina
SG11201700325SA (en) * 2014-08-08 2017-02-27 Glycovaxyn Ag Modified host cells and hybrid oligosaccharides for use in bioconjugate production
CN107427568B (zh) * 2015-01-15 2021-12-14 辉瑞公司 用于肺炎球菌疫苗中的免疫原性组合物
PE20220774A1 (es) 2015-05-04 2022-05-16 Pfizer Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos
IL319202A (en) 2015-11-17 2025-04-01 Pfizer Substrates for fermentation methods to create polysaccharides in bacterial cells
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
KR102437120B1 (ko) * 2016-08-05 2022-08-25 사노피 파스퇴르 인코포레이티드 다가 폐렴구균 다당류-단백질 접합체 조성물
ES3024474T3 (en) 2016-12-30 2025-06-04 Vaxcyte Inc Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US11413344B2 (en) 2017-01-20 2022-08-16 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
ES3048958T3 (en) 2017-01-31 2025-12-12 Merck Sharp & Dohme Llc Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
CN110225764A (zh) 2017-01-31 2019-09-10 默沙东公司 制备多糖-蛋白缀合物的方法
WO2018156465A1 (en) 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Polysaccharide-protein conjugates utilizing diphtheria toxin fragment b as a carrier
US20200061542A1 (en) 2017-02-24 2020-02-27 Merck Sharp & Dohme Corp. Methods for improving filterability of polysaccharide-protein conjugate reactions
PT3585803T (pt) 2017-02-24 2025-12-22 Merck Sharp & Dohme Formulações de vacina pneumocócica conjugada
CN110996992A (zh) 2017-08-16 2020-04-10 默沙东公司 肺炎球菌缀合物疫苗制剂
CN111065387B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
WO2019050813A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
AU2018328040B2 (en) 2017-09-07 2025-01-16 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
EP3678655A4 (en) 2017-09-07 2021-05-05 Merck Sharp & Dohme Corp. PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE CARRIER PROTEIN CONJUGATES
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
PT3678654T (pt) 2017-09-07 2024-08-05 Merck Sharp & Dohme Llc Polissacáridos pneumocócicos e sua utilização em conjugados imunogénicos de polissacárido-proteína transportadora
WO2019083865A1 (en) 2017-10-25 2019-05-02 Merck Sharp & Dohme Corp. VACCINES WITH ADJUVANT
TWI725359B (zh) 2017-12-06 2021-04-21 美商默沙東藥廠 包含肺炎鏈球菌多醣-蛋白結合物之組合物及其使用方法
JP7397000B2 (ja) 2018-04-30 2023-12-12 メルク・シャープ・アンド・ドーム・エルエルシー 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法
EP3787673A4 (en) 2018-04-30 2022-04-27 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
US12144855B2 (en) 2018-04-30 2024-11-19 Merck Sharp & Dohme Llc Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
US20210223262A1 (en) 2018-06-07 2021-07-22 Merck Sharp & Dohme Corp. Lyosphere critical reagent kit
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
GEAP202415690A (en) 2018-12-19 2024-01-10 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
MX2021014710A (es) 2019-06-05 2022-01-18 Merck Sharp & Dohme Llc Un conjugado inmunogenico de polisacarido de neumococo del serotipo 35b- proteina y proceso de conjugacion para preparar el mismo.
MX2021014948A (es) 2019-06-05 2022-01-24 Merck Sharp & Dohme Llc Metodos de tratamiento de pacientes con una composicion inmunogenica que protege contra el seroripo 29 de s. pneumoniae.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041003A2 (en) * 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
EP2865392A1 (en) * 2012-06-20 2015-04-29 SK Chemicals Co., Ltd. Polyvalent pneumococcal polysaccharide-protein conjugate composition
US20150202309A1 (en) * 2014-01-21 2015-07-23 Pfizer Inc. Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof
WO2017013548A1 (en) * 2015-07-21 2017-01-26 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof

Also Published As

Publication number Publication date
US20240139303A1 (en) 2024-05-02
KR20240011879A (ko) 2024-01-26
RU2019129503A (ru) 2021-03-24
WO2018156491A1 (en) 2018-08-30
US20200054733A1 (en) 2020-02-20
JP2023036953A (ja) 2023-03-14
JP7680185B2 (ja) 2025-05-20
CN110337307A (zh) 2019-10-15
EP3589314A4 (en) 2021-04-21
US11090374B2 (en) 2021-08-17
MX2023001947A (es) 2023-03-14
JP2024112952A (ja) 2024-08-21
US20210330777A1 (en) 2021-10-28
MX2023001948A (es) 2023-03-14
EP3589314A1 (en) 2020-01-08
JP2020514326A (ja) 2020-05-21
AU2018225099A1 (en) 2019-07-25
MX2019009867A (es) 2019-10-02
RU2019129503A3 (https=) 2021-06-25
US12295998B2 (en) 2025-05-13
CA3050120A1 (en) 2018-08-30
KR20190121330A (ko) 2019-10-25
JP7796163B2 (ja) 2026-01-08
BR112019017560A2 (pt) 2020-04-07
US20210330778A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
US12295998B2 (en) Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates
US12016914B2 (en) Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US20240108711A1 (en) Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CN118063638A (zh) 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
CN114025784A (zh) 用针对肺炎链球菌血清型29进行保护的免疫原性组合物治疗患者的方法
RU2774891C2 (ru) Повышение иммуногенности конъюгатов полисахарид streptococcus pneumoniae-белок
CA3123414C (en) Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: MERCK SHARP & DOHME LLC

Free format text: FORMER NAME(S): MERCK SHARP & DOHME CORP.

FGA Letters patent sealed or granted (standard patent)